SCHEMBL7130918

SCHEMBL7130918

NCCOc1ccc2c(c1)C(S(=O)(=O)c1ccccc1)CS2(O)O

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 5/20 0.40
ITGA2B P08514 5/20 0.40
CYP19A1 P11511 4/20 0.36
ESR1 P03372 3/20 0.36
ESR2 Q92731 3/20 0.36
TAAR1 Q96RJ0 1/20 0.36
LTA4H P09960 2/20 0.36
PLA2G2A P14555 1/20 0.36
FGFR1 P11362 1/20 0.35
HTR2A P28223 1/20 0.35
CYP3A4 P08684 1/20 0.34
HTR1A P08908 1/20 0.33
HTR7 P34969 1/20 0.33
KAT6A Q92794 1/20 0.33
PPARD Q03181 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7161203 0.99 ITGB3 (0.40) ITGB3ITGA2BCYP19A1ESR1ESR2
SCHEMBL7135473 0.91 ITGB3 (0.42) ITGB3ITGA2BCYP19A1ESR1ESR2
SCHEMBL7133293 0.91 KAT6A (0.39) HTR1AHTR7KAT6APPARD
Hydrochloric Acid SCHEMBL7160727 0.90 ITGB3 (0.42) ITGB3ITGA2BCYP19A1ESR1ESR2
SCHEMBL7132803 0.89 KAT6A (0.35) FGFR1HTR1AHTR7KAT6APPARD
SCHEMBL7130925 0.88 ITGB3 (0.39) ITGB3ITGA2BCYP19A1ESR1ESR2
SCHEMBL7131503 0.87 KAT6A (0.43) LTA4HHTR2AKAT6A
Hydrochloric Acid SCHEMBL7161197 0.87 ITGB3 (0.38) ITGB3ITGA2BCYP19A1ESR1ESR2
SCHEMBL7132185 0.86 TAAR1 (0.38) ITGB3ITGA2BCYP19A1ESR1ESR2
SCHEMBL7689835 0.86 KDM4E (0.45) ESR1ESR2LTA4HFGFR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO ITGB3 3260/4885ITGA2B 2276/4885CYP19A1 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.